Cephalon and Teva: One Provigil Fund, Several Settlements

The Cephalon Provigil antitrust settlement required Cephalon and Teva to provide $1.2 billion to resolve allegations of pay-for-delay agreements, with eligible private settlements counting toward that obligation. The Federal Trade Commission alleged that Cephalon paid generic challengers to delay competition to its branded drug, Provigil. Under the alleged bargain, purchasers lost the chance to buy cheaper generics while challengers received value for waiting. For someone inside the negotiations, the important connection is between what a challenger received and what it agreed to postpone. The settlement check tells only part of that story.

The court entered the settlement order on June 17, 2015. Teva, Cephalon’s ultimate corporate parent, agreed to be bound along with Cephalon. The order combined restrictions on future patent settlements with a fund designed to satisfy related claims. That combination explains both the conduct the government challenged and why the resulting payments are so easy to count twice.

How the Provigil Pay-for-Delay Scheme Worked

The Federal Trade Commission alleged that Cephalon used payments in patent settlements to delay the launch of generic equivalents of its branded drug, Provigil. The alleged trade was value for waiting: the challenger received something valuable while the branded product faced less immediate competition.

A reverse payment runs from the patent holder to the company challenging it. The company asserting that its patent has been infringed pays the alleged infringer to settle. As the Third Circuit explained in its account of pharmaceutical patent settlements, a generic challenger might otherwise win by showing that the patent was invalid or that its product did not infringe it. Earlier generic entry could then bring purchasers lower prices. Paying the challenger to wait can take that possibility away from everyone buying the drug.

The industry’s approval process gives those negotiations their stakes. A branded manufacturer submits a New Drug Application to the Food and Drug Administration, including safety and effectiveness information. A company seeking to sell a generic version can use an abbreviated application without producing its own safety and effectiveness data, while showing the required similarities to the branded drug and addressing its patents.

Those are the two commercial roles in the challenged bargain. One company holds the branded product’s position in the market. The other seeks entry that could undercut it. The patent settlement sets the agreed entry date, and the accompanying business agreements can explain why the challenger accepted it.

The Supreme Court’s 2013 ruling, expressly recognized in the Cephalon order, established that certain patent settlements can violate antitrust law. Settling a patent dispute did not put the commercial bargain beyond examination.

What the Federal Trade Commission Order Prohibited

The order prohibited Cephalon and Teva from entering covered patent settlements that combined a payment to the generic company with its agreement to refrain from researching, developing, manufacturing, marketing or selling the drug for any period. The restriction reached decisions made before a product appeared on a pharmacy shelf.

Its definition of payment covered money, goods and services, even where the generic company purported to provide value in return. It included transfers expressly tied to a patent settlement. The commercial agreement’s label did not decide whether it fell within that definition.

For a business-development or finance employee, that makes the surrounding transaction important. A transfer can appear as a purchase, a license or another commercial arrangement rather than a payment described as compensation for delay. What the parties exchanged, when they agreed to it and how it connected to the entry restriction explain the economics.

A Supply Deal Can Carry Value Across Drug Markets

The separate AndroGel dispute shows why a supply agreement can matter to a patent settlement. In that case, the Federal Trade Commission alleged that Teva accepted delayed entry for generic AndroGel in exchange for a valuable arrangement involving another drug, TriCor.

The Third Circuit’s September 2020 opinion describes the alleged exchange. Teva would drop its patent challenge and refrain from competing with AndroGel, while AbbVie would authorize Teva to sell a generic version of TriCor and supply it on agreed terms. Teva would pay production costs, an additional percentage of those costs and a royalty. The Commission nevertheless alleged that the opportunity was valuable to Teva and commercially costly to AbbVie.

The court allowed that reverse-payment theory to proceed. The Federal Trade Commission later withdrew the remaining claim in July 2021. The comparison is the alleged exchange: value in one product market could purchase delayed competition in another. A person responsible for the supply terms could know something essential to understanding the patent bargain.

Why Private Settlements Counted Toward the FTC Fund

The Provigil fund expressly credited qualifying payments in related cases. Adding the FTC headline to every private settlement would count some of the same money again.

The order’s fund provisions required an escrow account administered by the Commission or its agent. The amount deposited would be held in trust to satisfy related settlements and judgments. But the deposit was reduced by qualifying amounts Cephalon and Teva had already paid before the thirtieth day after entry of the order.

A binding promise could also earn a credit. If the companies had signed a binding settlement agreement or binding term sheet by that deadline, the agreed payment reduced the deposit even before the related case produced a completed payment.

That distinction matters to anyone reading the company’s settlement accounts. A credited agreement, an escrow deposit and a payment to purchasers can describe different stages of the same obligation. They do not automatically describe separate recoveries.

The State Settlement Came From the Same Escrow

The later multistate Provigil settlement drew on the earlier escrow. In its August 4, 2016 announcement, New Jersey described a $125 million settlement for 48 states and the District of Columbia, including $35 million for consumers. That allocation belonged inside the Federal Trade Commission fund’s accounting.

The order itself identified a direct-purchaser class case, an end-payor class case and other related claims. It also covered qualifying government investigations and litigation involving Provigil patents, FDA exclusivities and patent settlements. Different groups could pursue different claims over the same alleged restriction on competition, while the order connected their recoveries through the fund.

The practical point is who the payment compensated. Purchaser recoveries addressed the alleged harm from delayed competition.

The Commercial Records Behind the Bargain

The order required more than a payment. It required verified compliance reports and copies of certain additional agreements with the parties to patent settlements. Where a settlement restricted generic activity, the reporting requirement reached additional agreements entered within a year of the settlement.

The order also provided for access to business records and interviews with officers, directors and employees to assess compliance. Its list included ledgers, accounts, correspondence and memoranda. For an insider, those are recognizable parts of the business: what the deal was expected to earn, how its terms changed during negotiations and what the final agreement committed each company to do.

We examine that connection with you. A patent agreement can supply the entry date, while a commercial agreement supplies the value exchanged. Internal forecasts and negotiations can explain why those terms belonged together. The useful account connects the bargain to its implementation, including what happened to the planned generic launch.

How Much of a Settlement Does a Whistleblower Get?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The Provigil purchaser fund served a different purpose: compensating claims arising from the alleged delay in competition.

The same company name can appear in very different cases. Cephalon’s separate drug-marketing civil settlement resolved False Claims Act claims involving Medicare, Medicaid and other federal healthcare programs and four whistleblower cases. Those claims concerned off-label marketing of Actiq, Gabitril and Provigil. They were separate from the Federal Trade Commission’s patent-settlement allegations.

Teva’s later generic-drug price-fixing matter likewise involved different conduct. Its separate False Claims Act settlement addressed federal health care purchases affected by collusion. The connection between the company’s conduct and government-paid claims is what makes that distinction useful to an insider.

For someone with information about pharmaceutical agreements and government-paid claims, we assess the conduct, the payments and the potential whistleblower case together. Your view of the negotiations may explain the commercial bargain. Your knowledge of government purchases may reveal another part of the case. Our whistleblower experts connect those facts with pharmaceutical antitrust whistleblower lawyers whose experience fits the conduct.

You Know What the Deal Was Worth

Our whistleblower experts can examine the Provigil payment arrangement and the credits between recoveries without treating the same fund as several payments.